Xencor, Inc. has earned a $10 million milestone payment from Amgen, triggered by the submission of the IND Application for AMG 424, a humanized T cell–recruiting bispecific antibody targeting CD38 and CD3, which uses Xencor’s Bispecific XmAb Technology. “XmAb antibody Fc domains continue to enable our partners to create a broad range of drug candidates, in addition to driving our internal programs,” said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor....